Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA.
J Alzheimers Dis. 2018;62(2):745-756. doi: 10.3233/JAD-170834.
Many genetic studies for Alzheimer's disease (AD) have been focused on the identification of common genetic variants associated with AD risk and not on other aspects of the disease, such as age at onset or rate of dementia progression. There are multiple approaches to untangling the genetic architecture of these phenotypes. We hypothesized that the genetic architecture of rate of progression is different than the risk for developing AD dementia. To test this hypothesis, we used longitudinal clinical data from ADNI and the Knight-ADRC at Washington University, and we calculated PRS (polygenic risk score) based on the IGAP study to compare the genetic architecture of AD risk and dementia progression. Dementia progression was measured by the change of Clinical Dementia Rating Sum of Boxes (CDR)-SB per year. Out of the 21 loci for AD risk, no association with the rate of dementia progression was found. The PRS rate was significantly associated with the rate of dementia progression (β= 0.146, p = 0.03). In the case of rare variants, TREM2 (β= 0.309, p = 0.02) was also associated with the rate of dementia progression. TREM2 variant carriers showed a 23% faster rate of dementia compared with non-variant carriers. In conclusion, our results indicate that the recently identified common and rare variants for AD susceptibility have a limited impact on the rate of dementia progression in AD patients.
许多针对阿尔茨海默病(AD)的遗传研究都集中在识别与 AD 风险相关的常见遗传变异体上,而不是关注疾病的其他方面,例如发病年龄或痴呆进展速度。有多种方法可以理清这些表型的遗传结构。我们假设进展速度的遗传结构与发生 AD 痴呆的风险不同。为了检验这一假设,我们使用了 ADNI 和华盛顿大学 Knight-ADRC 的纵向临床数据,并根据 IGAP 研究计算了 PRS(多基因风险评分),以比较 AD 风险和痴呆进展的遗传结构。痴呆进展通过每年临床痴呆评定量表总和评分(CDR-SB)的变化来衡量。在 21 个 AD 风险相关的基因座中,没有发现与痴呆进展速度相关的关联。PRS 率与痴呆进展速度显著相关(β=0.146,p=0.03)。在罕见变异的情况下,TREM2(β=0.309,p=0.02)也与痴呆进展速度相关。与非变异携带者相比,TREM2 变异携带者的痴呆进展速度快 23%。总之,我们的结果表明,最近确定的 AD 易感性的常见和罕见变异体对 AD 患者的痴呆进展速度的影响有限。